Formed in 2012 Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of a novel vaccine to prevent bacterial infections, as well as medicines for treating cancers and lung infections associated with cystic fibrosis.
Source: Antimicrobial Resistance Challenge, 2018 and 2019; CMS Condition of Participation, 2019; Vaccines recommended to the CDC and HHS by the physicians of the Advisory Committee on Immunization Practices are covered by insurers; Lob et al. Diagn Microbiol Infect Dis 2016, 85, 459-465; Critchley et al. PLOS ONE, 2019, 14(12): e0220265. Jernigan et al. N Engl J Med. 2020;382(14):1309-1319.
In 2018 and 2019, the CDC and the United States Department of Health and Human Services (HHS) led the Antimicrobial Resistance Challenge to implement strategies to reduce the development of antibiotic resistance.
This Challenge received commitments from more than 300 healthcare systems, health insurance companies, medical professionals, and government health organizations. One of these commitments was to invest in the development and commercialization of vaccines.
The CDC supports the prevention of bacterial infections via immunizations. The CDC’s Core Elements of Hospital Antibiotic Stewardship program has encouraged hospitals to implement initiatives to help reduce antibiotic prescriptions in outpatient settings.
Today, the CDC continues to promote antimicrobial stewardship programs to reduce the use of antibiotics; however, UTI cases caused by multidrug-resistant extended-spectrum beta-lactamase Escherichia coli continue to rise because of the overuse of antibiotics.
The Advisory Committee on Immunization Practices (ACIP), which operates at the CDC to make recommendations regarding the adoption of new vaccines, considers the safety and effectiveness of every vaccine and the severity of the disease. Vaccine recommendations from the ACIP are generally adopted.
Our product pipeline includes programs that are designed to combat antimicrobial resistance and target bacterial infections, as well as broad anti-cancer therapeutics.
We solely own our patents that contain composition and method of use claims covering our vaccine and adjuvant.
1. U.S. Patent Numbers 9,017,698; 9,149,521; 9,149,522; 9,415,097; 9,415,101; 9,492,522; 9,504,743; 9,878,037; 10,058,608; 10,137,192; 10,525,128 and 11,110,169
Our esteemed leadership team possesses over 100 years of combined experience in pharmaceutical R&D and oversees the discovery and commercialization of our programs, collaborations, and optimization of our technologies.